Journal
NEUROLOGIC CLINICS
Volume 38, Issue 2, Pages 367-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.ncl.2020.01.010
Keywords
Huntington disease; Vesicular monoamine transporter type 2 inhibitors; Antipsychotic drugs; Deep brain stimulation; Antisense oligonucleotides
Categories
Ask authors/readers for more resources
Huntington disease, a neurodegenerative disease characterized by progressive motor, behavioral, and cognitive decline, is caused by a CAG trinucleotide repeat expansion in the huntingtin gene on chromosome 4. Current treatments target symptom management because there are no disease-modifying therapies at this time. Investigation of RNA-based and DNA-based treatment strategies are emerging and hold promise of possible future disease-modifying therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
